Hyper Lab Blog

Seladelpar, a treatment for Primary Biliary Cholangitis, has received FDA accelerated approval. This rare autoimmune disease, mainly affecting middle-aged women, is now addressed by seladelpar’s high selectivity and fewer side effects.

We describe the clinical development status and characteristics of seven new drugs first presented at EFMC-ISMC in 2024.

We interviewed Ryan Kern from the Georgia Institute of technology about the Hyper Lab, and how it integrates experimentation and computation, and has proven to be very useful in optimizing drug candidates.

EFMC-ISMC 2024 is an international pharmacology symposium taking place September 1-5 in Rome, Italy, and is divided into three main sessions. HITS will be introducing Hyper Lab, an AI drug discovery platform.

It's been a decade since AI entered the drug discovery race, but where are we in the pipeline of drugs discovered by AI-powered drug discovery platforms? In this post, we'll summarize the targets and trends in their development.

We interviewed Celine Evbuomwan and Caitlyn Santos, pharmacy students at Midwestern University, about the Hyper Lab. Their positive feedback was that the Hyper Lab is easy to use and well-stocked with tutorials.

In this Hyper Lab interview, José Antonio Costoya, Head of the Molecular Oncology Laboratory at the University of Santiago de Compostela CiMUS, talks about his research and the AI drug discovery platform Hyper Lab.

Here are three features that utilize Hyper Lab. You can prioritize experiments with hyper-binding, get drug structure suggestions with hyper-design, and see the binding structure of drugs and proteins with the 3D/2D viewer.

At the Drug Discovery Conference (DDC) 2024 and American Association of Cancer Research (AACR) 2024, held in April 2024, HITS unveiled Hyper Lab to the world. In this post, we will introduce a research scenario to demonstrate the use cases of Hyper Lab.

In this article, we analyze the posters submitted to DDC 2024, categorized by country, organization, and topic.